Translationell bröstcancerforskninlg: långsiktig risk och endokrin behandlingsnytta – Linda Lindströms forskargrupp

Article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(35):4071-4082

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.

Johansson A; Dar H; van 't Veer LJ; Tobin NP; Perez-Tenorio G; Nordenskjöld A; Johansson U; Hartman J; Skoog L; Yau C; Benz CC; Esserman LJ; Stål O; Nordenskjöld B; Fornander T; Lindström LS

Article: JAMA NETWORK OPEN. 2021;4(6):e2114904

Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.

Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS

Article: JAMA NETWORK OPEN. 2021;4(6):e2114716

Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden.

Johansson A; Christakou AE; Iftimi A; Eriksson M; Tapia J; Skoog L; Benz CC; Rodriguez-Wallberg KA; Hall P; Czene K; Lindström LS

Article: JAMA ONCOLOGY. 2019;5(9):1304-1309

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.

Yu NY; Iftimi A; Yau C; Tobin NP; van 't Veer L; Hoadley KA; Benz CC; Nordenskjöld B; Fornander T; Stål O; Czene K; Esserman LJ; Lindström LS

Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(7):726-733

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.

Lindström LS; Yau C; Czene K; Thompson CK; Hoadley KA; Van't Veer LJ; Balassanian R; Bishop JW; Carpenter PM; Chen Y-Y; Datnow B; Hasteh F; Krings G; Lin F; Zhang Y; Nordenskjöld B; Stål O; Benz CC; Fornander T; Borowsky AD; Esserman LJ; STO Trialists Group

Article: JAMA ONCOLOGY. 2017;3(11):1503-1510

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.

Esserman LJ; Yau C; Thompson CK; van 't Veer LJ; Borowsky AD; Hoadley KA; Tobin NP; Nordenskjöld B; Fornander T; Stål O; Benz CC; Lindström LS

Article: ANNALS OF ONCOLOGY. 2015;26(1):81-88

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.

Tobin NP; Harrell JC; Lövrot J; Egyhazi Brage S; Frostvik Stolt M; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Walz T; Fernö M; Perou CM; Bergh J; Hatschek T; Lindström LS; TEX Trialists Group

Article: ANNALS OF ONCOLOGY. 2014;25(10):1966-1972

Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer.

Lindström LS; Li J; Lee M; Einbeigi Z; Hartman M; Hall P; Czene K

Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(21):2601-2608

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J

Article: LANCET ONCOLOGY. 2007;8(11):1001-1006

Familial concordance in cancer survival: a Swedish population-based study.

Lindström LS; Hall P; Hartman M; Wiklund F; Grönberg H; Czene K

Translationell bröstcancerforskninlg: långsiktig risk och endokrin behandlingsnytta – Linda Lindströms forskargrupp

Publikationer

Utvalda publikationer

Medlemmar och kontakt

Gruppledare

Alla medlemmar i gruppen